These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

465 related items for PubMed ID: 25456951

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and SLC5A5 mRNA Expression.
    Tavares C, Eloy C, Melo M, Gaspar da Rocha A, Pestana A, Batista R, Bueno Ferreira L, Rios E, Sobrinho Simões M, Soares P.
    Int J Mol Sci; 2018 May 13; 19(5):. PubMed ID: 29757257
    [Abstract] [Full Text] [Related]

  • 5. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity.
    Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J, Su B.
    Cell; 2006 Oct 06; 127(1):125-37. PubMed ID: 16962653
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
    Degl'Innocenti D, Romeo P, Tarantino E, Sensi M, Cassinelli G, Catalano V, Lanzi C, Perrone F, Pilotti S, Seregni E, Pierotti MA, Greco A, Borrello MG.
    Endocr Relat Cancer; 2013 Feb 06; 20(1):23-37. PubMed ID: 23132790
    [Abstract] [Full Text] [Related]

  • 8. AKT activity is elevated in aggressive thyroid neoplasms where it promotes proliferation and invasion.
    Matson DR, Hardin H, Buehler D, Lloyd RV.
    Exp Mol Pathol; 2017 Dec 06; 103(3):288-293. PubMed ID: 29169802
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Morphoproteomics demonstrates activation of mammalian target of rapamycin pathway in papillary thyroid carcinomas with nuclear translocation of MTOR in aggressive histological variants.
    Liu J, Brown RE.
    Mod Pathol; 2011 Dec 06; 24(12):1553-9. PubMed ID: 21822208
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex.
    Liu P, Gan W, Chin YR, Ogura K, Guo J, Zhang J, Wang B, Blenis J, Cantley LC, Toker A, Su B, Wei W.
    Cancer Discov; 2015 Nov 06; 5(11):1194-209. PubMed ID: 26293922
    [Abstract] [Full Text] [Related]

  • 16. Gene expression in poorly differentiated papillary thyroid carcinomas.
    Fluge Ø, Bruland O, Akslen LA, Lillehaug JR, Varhaug JE.
    Thyroid; 2006 Feb 06; 16(2):161-75. PubMed ID: 16676402
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy.
    Siraj AK, Bavi P, Abubaker J, Jehan Z, Sultana M, Al-Dayel F, Al-Nuaim A, Alzahrani A, Ahmed M, Al-Sanea O, Uddin S, Al-Kuraya KS.
    J Pathol; 2007 Oct 06; 213(2):190-9. PubMed ID: 17703498
    [Abstract] [Full Text] [Related]

  • 20. mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR.
    Yin Y, Hua H, Li M, Liu S, Kong Q, Shao T, Wang J, Luo Y, Wang Q, Luo T, Jiang Y.
    Cell Res; 2016 Jan 06; 26(1):46-65. PubMed ID: 26584640
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.